Intraepithelial neoplasia

Novan Awarded Approximately $1.1 Million Grant by Department of Defense

Retrieved on: 
Friday, September 20, 2019
Infectious causes of cancer, Health, Intraepithelial neoplasia, Lesion, Cervical intraepithelial neoplasia, Cin, National Institutes of Health, Articles, Vaccines

The grant will support the development of a product candidate (WH504) for the treatment of cervical intraepithelial neoplasia (CIN), with well-characterized physical chemical properties suitable for intravaginal administration.

Key Points: 
  • The grant will support the development of a product candidate (WH504) for the treatment of cervical intraepithelial neoplasia (CIN), with well-characterized physical chemical properties suitable for intravaginal administration.
  • This grant is in addition to the previously announced National Institute of Health (NIH) Phase 1 grant of approximately $223,000 for the development of a separate product candidate (WH602).
  • Both product candidates will represent core initiatives within the previously announced Novan womens health business unit.
  • The views expressed in this press release are those of the Company and may not reflect the official policy or position of the Department of the Army, Department of Defense, or the U.S. Government.

Novan Advances Women’s Health Business Unit with Non-Dilutive Funding

Retrieved on: 
Wednesday, August 14, 2019
Infectious causes of cancer, Intraepithelial neoplasia, Lesion, Cervical intraepithelial neoplasia, Cin, Health, Clinical medicine

These grants will provide funding on a non-dilutive basis for specific initiatives within product advancement for the treatment of cervical intraepithelial neoplasia (CIN).

Key Points: 
  • These grants will provide funding on a non-dilutive basis for specific initiatives within product advancement for the treatment of cervical intraepithelial neoplasia (CIN).
  • Prospectively, Novan expects to be eligible to receive additional grant dollars for Phase 2 and 3 extensions.
  • Both product candidates will represent the core to Novans womens health business unit.
  • This unit will continue to be supported through a collaboration with Health Decisions, Inc. (Health Decisions).

Transgene: Peer-Reviewed Publications Confirm the Potential of Transgene’s TG4001 and TG6002

Retrieved on: 
Wednesday, June 5, 2019
Health, Biotechnology, Clinical trials, Infectious diseases, Oncology, Pharmaceutical, Other Health, Cancer, Medicine, Infectious causes of cancer, Papillomavirus, RTT, Vaccines, Gynaecological cancer, Cervical intraepithelial neoplasia, Human papillomavirus infection, Intraepithelial neoplasia, Precancerous condition, Oncolytic virus

The data confirm the potential of TG4001 (Tipapkinogen Sovacivec), administered as a monotherapy, to treat precancerous HPV-induced lesions (cervical intraepithelial neoplasia - CIN2/3).

Key Points: 
  • The data confirm the potential of TG4001 (Tipapkinogen Sovacivec), administered as a monotherapy, to treat precancerous HPV-induced lesions (cervical intraepithelial neoplasia - CIN2/3).
  • Irrespective of baseline HPV infection, viral DNA clearance2 was higher in the vaccine group compared to placebo (p
  • TG4001 was well tolerated with the most common adverse events being injection site reactions.
  • Harper, et al., Gynecologic Oncology -
    Transgene provides detailed preclinical data on its oncolytic virus TG6002.

Orion Biotechnology's Chief Medical Officer to Present at the American Society of Clinical Oncology (ASCO) Meeting in Chicago

Retrieved on: 
Thursday, May 30, 2019
Cancer, Infectious causes of cancer, Papillomavirus, Gastrointestinal cancer, Anal cancer, RTT, Oncology, Intraepithelial neoplasia, Anal dysplasia, Human papillomavirus infection, Dysplasia, Anal Pap smear

His talk will be in the Gastrointestinal (Colorectal) cancer track and will focus on the surveillance and management of anal intraepithelial neoplasia in HIV and non-HIV infected patients.

Key Points: 
  • His talk will be in the Gastrointestinal (Colorectal) cancer track and will focus on the surveillance and management of anal intraepithelial neoplasia in HIV and non-HIV infected patients.
  • In the MTN-017 study which was conducted in the US, Peru, Thailand, and South Africa.
  • Dr. McGowan's laboratory showed that approximately 93% of MSM had evidence of anal HPV infection which is linked to the development of anal dysplasia and anal cancer (Cranston et al.
  • These patients should undergo regular surveillance to recognize and treat anal dysplasia to avoid progression to anal cancer," said Dr. McGowan.

Orion Biotechnology's Chief Medical Officer to Present at the American Society of Clinical Oncology (ASCO) Meeting in Chicago

Retrieved on: 
Thursday, May 30, 2019
Cancer, Infectious causes of cancer, Papillomavirus, Gastrointestinal cancer, Anal cancer, RTT, Oncology, Intraepithelial neoplasia, Anal dysplasia, Human papillomavirus infection, Dysplasia, Anal Pap smear

His talk will be in the Gastrointestinal (Colorectal) cancer track and will focus on the surveillance and management of anal intraepithelial neoplasia in HIV and non-HIV infected patients.

Key Points: 
  • His talk will be in the Gastrointestinal (Colorectal) cancer track and will focus on the surveillance and management of anal intraepithelial neoplasia in HIV and non-HIV infected patients.
  • In the MTN-017 study which was conducted in the US, Peru, Thailand, and South Africa.
  • Dr. McGowan's laboratory showed that approximately 93% of MSM had evidence of anal HPV infection which is linked to the development of anal dysplasia and anal cancer (Cranston et al.
  • These patients should undergo regular surveillance to recognize and treat anal dysplasia to avoid progression to anal cancer," said Dr. McGowan.

Global Women's Health Drugs Market to 2024 - Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive Growth

Retrieved on: 
Monday, January 21, 2019
RTT, Chemistry, Medicine, Women\'s health, Cervical intraepithelial neoplasia, Intraepithelial neoplasia, Infertility, Polycystic ovary syndrome, Endometriosis, Cin, Elagolix, Ovarian cancer

The "Global Women's Health Drugs Market to 2024 - Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive Growth" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Women's Health Drugs Market to 2024 - Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive Growth" report has been added to ResearchAndMarkets.com's offering.
  • "Global Women's Health Drugs Market to 2024" covers all indications within women's health with a particular focus on five key indications: endometriosis, polycystic ovarian syndrome (PCOS), cervical intraepithelial neoplasia (CIN), menopausal disorders and infertility.
  • There are currently 277 pipeline products in active development for women's health, making it the 16th largest therapy area by pipeline size.
  • The global market is projected to grow at a compound annual growth rate (CAGR) of 5.16% till 2024.

Frontier Pharma: Women's Health - An Expanding Therapy Area, with Endometriosis Therapies Prominent among the First-in-Class Pipeline

Retrieved on: 
Wednesday, January 9, 2019
RTT, Women\'s health, Medicine, Health, Menstrual cycle, Gynaecological cancer, Endometriosis, Polycystic ovary syndrome, Intraepithelial neoplasia, Cervical intraepithelial neoplasia, Ovarian cancer, Menopause

NEW YORK, Jan. 9, 2019 /PRNewswire/ -- Frontier Pharma: Women's Health - An Expanding Therapy Area, with Endometriosis Therapies Prominent among the First-in-Class Pipeline

Key Points: 
  • NEW YORK, Jan. 9, 2019 /PRNewswire/ -- Frontier Pharma: Women's Health - An Expanding Therapy Area, with Endometriosis Therapies Prominent among the First-in-Class Pipeline
    The women's health therapy area covers medical disorders that affect females only, primarily disorders of the female reproductive system, including those associated with menstruation, conception, pregnancy, childbirth and menopause.
  • This reflects diagnostic barriers and high levels of non-treatment for women's health disorders, as well as high levels of genericization and relatively limited innovation within recent decades.
  • Consequently, there is strong rationale for continued R&D investment in women's health therapeutics due to high levels of unmet need across many indications.
  • This report assesses first-in-class innovation across the women's health therapy area, with a particular focus on three key indications: endometriosis, polycystic ovarian syndrome (PCOS) and cervical intraepithelial neoplasia (CIN).

Global Cytology Market 2018-2022 - Growing Popularity of Co-Testing / Consolidation and Automation of Laboratories / Advent of Cytology Imaging Systems

Retrieved on: 
Wednesday, December 19, 2018
Cancer, Infectious causes of cancer, Gynaecological cancer, RTT, Cytopathology, Medical tests, Pap test, Cervical cancer, Cervical intraepithelial neoplasia, Human papillomavirus infection, Intraepithelial neoplasia, Screening

The cytology market will register a CAGR of nearly 7% by 2022.

Key Points: 
  • The cytology market will register a CAGR of nearly 7% by 2022.
  • Pap test is used as a screening tools for cervical cancer has improved detection of cervical intraepithelial neoplasia.
  • Therefore, a substantial increase of HPV- associated cancers propels the demand for cytology testing and screenings methods.
  • According to the report, one of the major drivers for this market is the growing preference for liquid- based cytology tests.